Growth Portfolio Offsets Patent Cliffs as 2026 Data Wave Nears (BMY Q4 2025 Earnings Call)

By Dr. Graph | Updated on Apr 14, 2026 | earnings

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Bristol-Myers Squibb reported a highly transitional fourth quarter, showcasing the company's aggressive pivot toward its newer therapeutic portfolio. Faced with structural generic pressure, the pharmaceutical manufacturer leaned on its recently launched oncology and immunology assets to stabilize top-line performance. While management guided for a catalyst-rich 2026, impending exclusivity losses for the Eliquis franchise continue to cast a shadow over long-term international revenue.

New Growth Portfolio Defends Against Generic Pressures

Corporate financial execution proved resilient during the fourth quarter, as Bristol-Myers Squibb delivered flat total revenue of $12.5 billion. Crucially, the company's strategic growth portfolio experienced a powerful acceleration, surging 15% year-over-year to generate $7.4 billion. These newer assets—which include Reblozyl, Opdualag, and Breyanzi—now account for nearly 60% of total commercial revenue, offsetting legacy portfolio declines driven by the ongoing Revlimid patent cliff.

Balanced Fiscal 2026 Outlook and Aggressive Cost Cutting

Navigating these complex commercial crosscurrents, management issued fiscal 2026 revenue guidance spanning $46.0 billion to $47.5 billion. This outlook incorporates a projected 12% to 16% core decline across the legacy portfolio. Strategically maximizing bottom-line efficiency, management established an adjusted earnings per share target of $6.05 to $6.35, supported by an ongoing corporate productivity initiative designed to reduce gross operating expenses.

Solid Eliquis Near-Term Performance Precedes 2027 Cliff

The legacy cardiovascular blockbuster Eliquis delivered a strong fourth quarter, generating $3.5 billion in global commercial sales, which represents a 6% year-over-year expansion. While United States pricing dynamics project structural Eliquis revenue to grow 10% to 15% throughout 2026, management offered a highly cautious forward outlook. Specifically, due to impending European Union patent expirations late next year, analysts and executives predict a revenue step-down of $1.5 billion to $2.0 billion hitting the franchise in 2027.

Unprecedented 2026 Clinical Data Explosion

Looking forward, executive management guided for a robust clinical sequence in 2026, projecting pivotal top-line registrational data across six major late-stage pipeline candidates. The corporate pipeline will see Phase 3 inflection readouts for highly anticipated assets including Milvexian for atrial fibrillation and Edmilparant for idiopathic pulmonary fibrosis. Furthermore, multiple advanced CELMoD therapies targeting refractory multiple myeloma will read out, fundamentally defining the company's commercial profile into the next decade.

Frequently Asked Questions

How did Bristol-Myers offset significant legacy product revenue erosion in Q4?

CFO David Elkins noted that a 15% organic surge across the broader strategic growth portfolio captured $7.4 billion in Q4 revenue, representing nearly 60% of total revenue and fully offsetting major legacy LOE headwinds.

What specific headwind did management project for Eliquis in 2027?

CFO David Elkins confirmed that due to major European exclusivity patent expirations late in 2026, management expects a global revenue step-down of $1.5 billion to $2.0 billion for Eliquis in 2027.

What did Bristol-Myers project for total 2026 financial performance?

CEO Christopher Boerner guided for total organic full-year commercial revenue between $46.0 billion and $47.5 billion, while forecasting an adjusted EPS range of $6.05 to $6.35.